CD44 and breast carcinoma: Apart from CD44+CD24−/low and ALDH1+, various markers have been reported to identify and isolate BCSCs in human and mouse breast cancer, which supports further research on BCSCs and provides a premise for clinical BCSC targeting (Table 1).